Combination treatment for myeloproliferative neoplasms using JAK and pan‐class I PI 3K inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination treatment for myeloproliferative neoplasms using JAK and pan‐class I PI 3K inhibitors

Published:2013-11 Issue:11 Volume:17 Page:1397-1409
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J. Cell. Mol. Med.

Author:

Choong Meng Ling¹,Pecquet Christian²,Pendharkar Vishal¹,Diaconu Carmen C.²³,Yong Jacklyn Wei Yan¹,Tai Shi Jing¹,Wang Si Fang¹,Defour Jean‐Philippe²,Sangthongpitag Kanda¹,Villeval Jean‐Luc⁴,Vainchenker William⁴,Constantinescu Stefan N.²,Lee May Ann¹

Affiliation:

1. Experimental Therapeutics Centre Agency for Science Technology and Research Singapore

2. Ludwig Institute for Cancer Research & de Duve Institute UniversitéCatholique de Louvain Brussels Belgium

3. Stefan S. Nicolau Institute of Virology Bucharest Romania

4. INSERM U1009 InstitutGustaveRoussy Université Paris‐Sud Villejuif Cedex France

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.12156

Reference59 articles.

1. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

2. A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

4. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

5. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FOXA1 prolongs S phase and promotes cancer progression in non‐small cell lung cancer through upregulation of CDC5L and activation of the ERK1/2 and JAK2 pathways;The Kaohsiung Journal of Medical Sciences;2023-09-02

2. PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis;Clinical Cancer Research;2023-04-10

3. HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode;Bioorganic Chemistry;2022-12

4. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line;Molecular Biology Reports;2022-11-04

5. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 cells;2022-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3